Bob T. Li, MD, PhD, MPH, discusses the results of the phase 2 DESTINY-Lung01 trial in HER2-positive metastatic non–small cell lung cancer.
Bob T. Li, MD, PhD, MPH, medical oncologist, physician ambassador to China and Asia-Pacific, Bobst International Center, co-director, Thoracic Liquid Biopsy Program, chief scientific officer, MSK Direct, Memorial Sloan Kettering Cancer Center, discusses the results of the phase 2 DESTINY-Lung01 trial (NCT03505710) in HER2-positive metastatic non–small cell lung cancer (NSCLC).
Findings from the DESTINY-Lung01 trial, which were presented during the 2021 ESMO Congress, demonstrated robust and durable anticancer activity with the antibody-drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with previously treated HER2-mutated NSCLC. Moreover, efficacy was consistently observed across patient subgroups, including in those with central nervous system metastases.
Drug-related interstitial lung disease (ILD) and pneumonitis were generally low-grade and manageable; however, early detection and management is important to prevent serious ILD and pneumonitis among patients.
Although cytotoxic agents are often difficult to tolerate, ADCs like trastuzumab deruxtecan, which link a cytotoxic chemotherapy payload to a trastuzumab (Herceptin) antibody, appear to be well tolerated and elicit clinically meaningful activity in patients with HER2-positive NSCLC. Moreover, these data represent an encouraging step forward in the treatment of this patient population, Li concludes.